BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

J Yang, W Zhou, D Li, T Niu, W Wang - Cancer Letters, 2023 - Elsevier
Multiple myeloma (MM) remains an incurable hematologic malignancy, despite the
development of numerous innovative therapies during the past two decades …

Innovation in BCMA CAR-T therapy: Building beyond the Model T

R Banerjee, SS Lee, AJ Cowan - Frontiers in Oncology, 2022 - frontiersin.org
Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation
antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the …

Chimeric antigen receptor T cells in multiple myeloma

P Shah, AS Sperling - Hematology/Oncology Clinics, 2023 - hemonc.theclinics.com
Chimeric Antigen Receptor T Cells in Multiple Myeloma - Hematology/Oncology Clinics Skip to
Main Content Advertisement Hematology/Oncology Clinics Log in Register Log in Subscribe …

Genome-Edited T Cell Therapies

G Ottaviano, W Qasim - Hematology/Oncology Clinics, 2022 - hemonc.theclinics.com
Genome editing offers the prospect of enhanced gene therapy and new therapeutic avenues
beyond those envisaged by conventional 'gene-addition'strategies. The breakthrough …

[HTML][HTML] Allogeneic and other innovative chimeric antigen receptor platforms

AP Jallouk, S Sengsayadeth, BN Savani… - Clinical Hematology …, 2024 - pmc.ncbi.nlm.nih.gov
Allogeneic and other innovative chimeric antigen receptor platforms - PMC Skip to main content
Here's how you know Official websites use .gov A .gov website belongs to an official government …

A DNS transzpozonok funkcionális vizsgálata emlős sejtekben

P Lávay - 2024 - huveta.hu
A DNS transzpozonok olyan mobilis genetikai elemek, melyek kulcsszerepet játszanak
számos genomi folyamatban, ideértve a gazdagenomok evolúcióját is. A piggyBac …